Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KC7F2 是缺氧诱导因子HIF-1通道抑制剂,在 LN229-HRE-AP 细胞中的IC50=20 μM,可用作抗癌试剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 319 | 现货 | ||
10 mg | ¥ 463 | 现货 | ||
25 mg | ¥ 792 | 现货 | ||
50 mg | ¥ 1,380 | 现货 | ||
100 mg | ¥ 2,360 | 现货 | ||
200 mg | ¥ 3,520 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | KC7F2 is a potent HIF-1 pathway inhibitor with potential anti-cancer activity. |
靶点活性 | HIF1α:20 μM |
体外活性 | KC7F2在LN229-HRE-AP细胞中抑制HRE驱动的转录并降低HIF-1α蛋白水平。对于MCF7、LNZ308、A549、U251 mg和LN229癌细胞,KC7F2表现出剂量响应性细胞毒性,IC50约为15至25μM。在D54 mg胶质瘤细胞中,尤其在缺氧条件下,KC7F2抑制了集落形成。[1] 在缺氧的小胶质细胞培养中,KC7F2下调TfR和DMT的表达,并减少了HIF-1α介导的铁积累。[2] |
体内活性 | KC7F2在戊四氮癫痫模型大鼠中显著缩短潜伏期,并在慢性阶段增加了锂-毛果芸香碱大鼠模型中自发性复发性癫痫的发作率。[3] |
激酶实验 | HIF transcriptional activity assay: Cells are incubated at 37 in a humidified atmosphere containing 5% CO2 and 21% O2 (normoxia) or 1% O2 (hypoxia) in a hypoxia workstation. The LN229-HRE-AP reporter cell line for HIF transcriptional activity is created by stably transfecting LN229 cells with the pACN188 plasmid, which contains an alkaline phosphatase gene driven by six HREs derived from the VEGF gene. |
细胞实验 | Cells are seeded onto 96-well plates (4 × 103/well) and cultured under normoxic (21% O2) and hypoxic (1% O2) conditions with different concentrations of KC7F2 for 72 h or treated for various times with 20 μM KC7F2. For proliferation analysis, cells are fixed with 50% trichloroacetic acid for 1 h at 4°C, followed by staining with 0.4% sulforhodamine B dissolved in 1% acetic acid for 30 min at room temperature. Plates are washed five times with 1% acetic acid to remove unbound dye. Bound dye is dissolved by adding 10 mM unbuffered Tris base. Cell proliferation is calculated by measuring OD values at 564 nm using a spectrophotometer.(Only for Reference) |
分子量 | 570.38 |
分子式 | C16H16Cl4N2O4S4 |
CAS No. | 927822-86-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 57 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7532 mL | 8.7661 mL | 17.5322 mL | 43.8304 mL |
5 mM | 0.3506 mL | 1.7532 mL | 3.5064 mL | 8.7661 mL | |
10 mM | 0.1753 mL | 0.8766 mL | 1.7532 mL | 4.383 mL | |
20 mM | 0.0877 mL | 0.4383 mL | 0.8766 mL | 2.1915 mL | |
50 mM | 0.0351 mL | 0.1753 mL | 0.3506 mL | 0.8766 mL | |
100 mM | 0.0175 mL | 0.0877 mL | 0.1753 mL | 0.4383 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KC7F2 927822-86-4 Angiogenesis Chromatin/Epigenetic Metabolism HIF HIF/HIF Prolyl-Hydroxylase HIFs Inhibitor Hypoxia-inducible factors inhibit HIF-PH KC-7F2 inhibitor